Skip to main content

Advertisement

SpringerLink
Log in

Phenotypes and Natural Evolution of Drug Hypersensitivity

  • Drug Allergy (L Mayorga, Section Editor)
  • Published:
Current Treatment Options in Allergy Aims and scope Submit manuscript

Abstracts

Purpose of review

Drug hypersensitivity reactions (DHRs) are adverse effects that clinically resemble allergy. They belong to type B adverse drug reactions, which are dose-independent and unpredictable. Misclassification of DHR may lead to under and/or overdiagnosis, which affects the management of patients, leading to higher risk of suffering an allergic reaction or the use of alternative more-expensive and potentially less-effective drugs. A precise phenotype of DHR is required for a better evaluation and proper management of patients experiencing DHR. The purpose of this review is to summarise the different phenotypes of DHR basing on different criterions.

Recent findings

The phenotyping of DHRs is challenging as clinical presentations are heterogeneous, the underlying mechanism is poorly understood and terminology varies among different studies. Moreover, natural evolution may be different depending on the phenotype.

Summary

This review summarises the complexity of DHR phenotyping, which can be based on different criterions as chronology, mechanism and clinical symptoms as well as natural evolution. A precise phenotyping of DHR is needed to determine the adequate evaluation and management of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. International drug monitoring. The role of national centres Report of a WHO meeting. World Health Organ Tech Rep Ser. 1972;498:1–25.

    Google Scholar 

  2. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7):1017–25.

    Article  PubMed  Google Scholar 

  3. Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol. 2005;5(4):309–16.

    Article  PubMed  Google Scholar 

  4. Hakkarainen KM, Hedna K, Petzold M, Hägg S. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions--a meta-analysis. PLoS One. 2012;7(3):e33236.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Rawlins MD, T.J., Pathogenesis of adverse drug reactions, in Textbook of adverse drug reactions, D. DM, Editor. 1977, Oxford University Press: Oxford. p. 10.

  6. Bernstein JA. Nonimmunologic adverse drug reactions. How to recognize and categorize some common reactions. Postgrad Med. 1995;98(1):120–2 125-6.

  7. •• Demoly P, et al. International consensus on drug allergy. Allergy. 2014;69(4):420–37 In this position paper, the International Collaboration in Asthma, Allergy and Immunology (iCAALL) critically reviewed guidelines and consensus documents on DHR and compiled an International CONsensus (ICON) providing recommendations on drug allergy.

    Article  CAS  PubMed  Google Scholar 

  8. Joint Task Force on Practice, P, et al. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105(4):259–73.

    Article  Google Scholar 

  9. Bernstein JA. Allergic drug reactions. How to minimize the risks. Postgrad Med. 1995;98(2):159–60 163-6.

  10. deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA. 1997;278(22):1895–906.

    Article  CAS  PubMed  Google Scholar 

  11. Gomes E, Cardoso MF, Praca F, Gomes L, Marino E, Demoly P. Self-reported drug allergy in a general adult Portuguese population. Clin Exp Allergy. 2004;34(10):1597–601.

    Article  CAS  PubMed  Google Scholar 

  12. Johansson SG, et al. Revised nomenclature for allergy for global use: report of the nomenclature review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832–6.

    Article  CAS  PubMed  Google Scholar 

  13. Coombs PR, G.P., Classification of allergic reactions responsible for clinical hypersensitivity and disease. . In: Gell RR, editor. Clinical aspects of immunology. Oxford (UK): Oxford University Pess;, 1968: p. 575–96.

  14. •• Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139(8):683–93 In this review, concepts of the role of T-cells in various drug-induced hypersensitivity diseases are described.

    Article  CAS  PubMed  Google Scholar 

  15. Doña I, Blanca-López N, Cornejo-García JA, Torres MJ, Laguna JJ, Fernández J, et al. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy. 2011;41(1):86–95.

    Article  CAS  PubMed  Google Scholar 

  16. •• Kowalski ML, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68(10):1219–32 This position paper provides a classification of reactions induced by NSAIDs based on clinical manifestations and suspected mechanism.

    Article  CAS  PubMed  Google Scholar 

  17. Pichler WJ, Beeler A, Keller M, Lerch M, Posadas S, Schmid D, et al. Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol Int. 2006;55(1):17–25.

    Article  CAS  PubMed  Google Scholar 

  18. Blanca M, Romano A, Torres MJ, Férnandez J, Mayorga C, Rodriguez J, et al. Update on the evaluation of hypersensitivity reactions to betalactams. Allergy. 2009;64(2):183–93.

    Article  CAS  PubMed  Google Scholar 

  19. Torres MJ, Blanca M, Fernandez J, Romano A, Weck A, Aberer W, et al. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy. 2003;58(10):961–72.

    Article  CAS  PubMed  Google Scholar 

  20. Romano A, Blanca M, Torres MJ, Bircher A, Aberer W, Brockow K, et al. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy. 2004;59(11):1153–60.

    Article  CAS  PubMed  Google Scholar 

  21. Limsuwan T, Demoly P. Acute symptoms of drug hypersensitivity (urticaria, angioedema, anaphylaxis, anaphylactic shock). Med Clin North Am. 2010;94(4):691–710 x.

  22. • Blanca-Lopez N, et al. Allergic reactions to Metamizole: immediate and delayed responses. Int Arch Allergy Immunol. 2016;169(4):223–30 In this paper, a clinical characterization of allergic reactions to metamizol is performed, describing the symptoms induced by the drug. In this paper, the authors also discuss about the time interval between the drug intake and the onset of the reaction.

    Article  CAS  PubMed  Google Scholar 

  23. Ariza A, García-Martín E, Salas M, Montañez MI, Mayorga C, Blanca-Lopez N, et al. Pyrazolones metabolites are relevant for identifying selective anaphylaxis to metamizole. Sci Rep. 2016;6:23845.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Bircher AJ, Scherer Hofmeier K. Drug hypersensitivity reactions: inconsistency in the use of the classification of immediate and nonimmediate reactions. J Allergy Clin Immunol. 2012;129(1):263–4 author reply 265-6.

  25. Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges. 2009;7(2):142–60 quiz 161-2.

  26. Bircher AJ, Scherer K. Delayed cutaneous manifestations of drug hypersensitivity. Med Clin North Am. 2010;94(4):711–25 x.

  27. Bircher AJ. Uncomplicated drug-induced disseminated exanthemas. Chem Immunol Allergy. 2012;97:79–97.

    Article  CAS  PubMed  Google Scholar 

  28. •• Zalewska-Janowska A, Spiewak R, Kowalski ML. Cutaneous manifestation of drug allergy and hypersensitivity. Immunol Allergy Clin N Am. 2017;37(1):165–81 In this review, the clinical characteristic and mechanisms involved in allergic and non-allergic hypersensitivity reactions to drugs are summarized.

    Article  Google Scholar 

  29. Schnyder B. Approach to the patient with drug allergy. Med Clin North Am. 2010;94(4):665–79 xv.

  30. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209(2):123–9.

    Article  CAS  PubMed  Google Scholar 

  31. • Setkowicz M, et al. Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years. J Allergy Clin Immunol. 2009;123(1):174–8 In this study, it is analyzed the natural evolution of aspirin hypersensitivity in patients with NSAIDs-induced urticaria and underlying chronic spontaneous urticaria (NECD).

    Article  CAS  PubMed  Google Scholar 

  32. Khan DA, Solensky R. Drug allergy. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S126–37.

    Article  PubMed  Google Scholar 

  33. Fisher MM, Baldo BA. The incidence and clinical features of anaphylactic reactions during anesthesia in Australia. Ann Fr Anesth Reanim. 1993;12(2):97–104.

    Article  CAS  PubMed  Google Scholar 

  34. Mertes PM, et al. Perioperative anaphylaxis. Med Clin North Am. 2010;94(4):761–89 xi.

  35. Laguna JJ, Archilla J, Doña I, Corominas M, Gastaminza G, Mayorga C, et al. Practical guidelines for perioperative hypersensitivity reactions. J Investig Allergol Clin Immunol. 2018;28(4):216–32.

    Article  CAS  PubMed  Google Scholar 

  36. •• Montanez MI, et al. Epidemiology, mechanisms, and diagnosis of drug-induced anaphylaxis. Front Immunol. 2017;8:614 This review focuses in mechanisms involved and management of anaphylaxis induced by drugs.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Ewan PW, Dugué P, Mirakian R, Dixon TA, Harper JN, Nasser SM, et al. BSACI guidelines for the investigation of suspected anaphylaxis during general anaesthesia. Clin Exp Allergy. 2010;40(1):15–31.

    Article  CAS  PubMed  Google Scholar 

  38. Bonadonna P, Lombardo C, Bortolami O, Bircher A, Scherer K, Barbaud A, et al. Hypersensitivity to proton pump inhibitors: diagnostic accuracy of skin tests compared to oral provocation test. J Allergy Clin Immunol. 2012;130(2):547–9.

    Article  CAS  PubMed  Google Scholar 

  39. Blanca-Lopez N, et al. Hypersensitivity reactions to fluoroquinolones: analysis of the factors involved. Clin Exp Allergy. 2013;43(5):560–7.

    Article  CAS  PubMed  Google Scholar 

  40. Doña I, et al. Trends in hypersensitivity drug reactions: more drugs, more response patterns more heterogeneity. J Investig Allergol Clin Immunol. 2014;24(3):143–53 quiz 1 p following 153.

  41. Caubet JC, Kaiser L, Lemaître B, Fellay B, Gervaix A, Eigenmann PA. The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge. J Allergy Clin Immunol. 2011;127(1):218–22.

    Article  CAS  PubMed  Google Scholar 

  42. Dona I, et al. NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organs. Sci Rep. 2018;8(1):16710.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Yoshimine F, et al. Contribution of aspirin-intolerant asthma to near fatal asthma based on a questionnaire survey in Niigata prefecture, Japan. Respirology. 2005;10(4):477–84.

    Article  PubMed  Google Scholar 

  44. Fiszenson-Albala F, Auzerie V, Mahe E, Farinotti R, Durand-Stocco C, Crickx B, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol. 2003;149(5):1018–22.

    Article  CAS  PubMed  Google Scholar 

  45. •• Peter JG, et al. Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice. J Allergy Clin Immunol Pract. 2017;5(3):547–63 In this review, the clinical features, underlying mechanisms and management of severe delayed reactions to drugs are described.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Hausermann P, Bircher AJ. SDRIFE - another acronym for a distinct cutaneous drug exanthema: do we really need it? Dermatology. 2007;214(1):1–2.

    Article  PubMed  Google Scholar 

  47. Hausermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis. 2004;51(5–6):297–310.

    Article  CAS  PubMed  Google Scholar 

  48. Thyssen JP, Maibach HI. Drug-elicited systemic allergic (contact) dermatitis--update and possible pathomechanisms. Contact Dermatitis. 2008;59(4):195–202.

    Article  CAS  PubMed  Google Scholar 

  49. • Paulmann M, Mockenhaupt M. Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy. J Dtsch Dermatol Ges. 2015;13(7):625–45 In this review, clinical features and drug involved in severe drug-induced skin reactions are described.

    PubMed  Google Scholar 

  50. Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JNB, Naldi L, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157(5):989–96.

    Article  CAS  PubMed  Google Scholar 

  51. Halevy S. Acute generalized exanthematous pustulosis. Curr Opin Allergy Clin Immunol. 2009;9(4):322–8.

    Article  PubMed  Google Scholar 

  52. Momin SB, del Rosso J, Michaels B, Mobini N. Acute generalized exanthematous pustulosis: an enigmatic drug-induced reaction. Cutis. 2009;83(6):291–8.

    PubMed  Google Scholar 

  53. Roujeau JC, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol. 1991;127(9):1333–8.

    Article  CAS  PubMed  Google Scholar 

  54. Britschgi M, Steiner UC, Schmid S, Depta JPH, Senti G, Bircher A, et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest. 2001;107(11):1433–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Schmid S, Kuechler PC, Britschgi M, Steiner UC, Yawalkar N, Limat A, et al. Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am J Pathol. 2002;161(6):2079–86.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–6.

    Article  CAS  PubMed  Google Scholar 

  57. Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126(1):43–7.

    Article  CAS  PubMed  Google Scholar 

  58. Mittmann N, Knowles SR, Koo M, Shear NH, Rachlis A, Rourke SB. Incidence of toxic epidermal necrolysis and Stevens-Johnson syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012;13(1):49–54.

    Article  PubMed  Google Scholar 

  59. Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol. 1997;24(11):726–9.

    Article  CAS  PubMed  Google Scholar 

  60. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bavinck JNB, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35–44.

    Article  CAS  PubMed  Google Scholar 

  61. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58(1):25–32.

    Article  PubMed  Google Scholar 

  62. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071–80.

    Article  CAS  PubMed  Google Scholar 

  63. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156(3):609–11.

    Article  CAS  PubMed  Google Scholar 

  64. Kano Y, Hiraharas K, Sakuma K, Shiohara T. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol. 2006;155(2):301–6.

    Article  CAS  PubMed  Google Scholar 

  65. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology. 1997;49(2):542–6.

    Article  CAS  PubMed  Google Scholar 

  66. Guberman AH, Besag FMC, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia. 1999;40(7):985–91.

    Article  CAS  PubMed  Google Scholar 

  67. Brahimi N, Routier E, Raison-Peyron N, Tronquoy AF, Pouget-Jasson C, Amarger S, et al. A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol. 2010;20(4):461–4.

    PubMed  Google Scholar 

  68. Khaled A, Kharfi M, Ben Hamida M, el Fekih N, el Aidli S, Zeglaoui F, et al. Cutaneous adverse drug reactions in children. A series of 90 cases. Tunis Med. 2012;90(1):45–50.

    PubMed  Google Scholar 

  69. Lipowicz S, Sekula P, Ingen-Housz-Oro S, Liss Y, Sassolas B, Dunant A, et al. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2013;168(4):726–32.

    Article  CAS  PubMed  Google Scholar 

  70. Calabrese LH, Duna GF. Drug-induced vasculitis. Curr Opin Rheumatol. 1996;8(1):34–40.

    Article  CAS  PubMed  Google Scholar 

  71. Martinez-Taboada VM, et al. Clinical features and outcome of 95 patients with hypersensitivity vasculitis. Am J Med. 1997;102(2):186–91.

    Article  CAS  PubMed  Google Scholar 

  72. Johnson DH, Cunha BA. Drug fever. Infect Dis Clin N Am. 1996;10(1):85–91.

    Article  CAS  Google Scholar 

  73. Podevin P, Biour M. Drug-induced "allergic hepatitis". Clin Rev Allergy Immunol. 1995;13(3):223–44.

    CAS  PubMed  Google Scholar 

  74. Parra FM, Igea JM, Martin JA, Alonso MD, Lezaun A, Sainz T. Serum sickness-like syndrome associated with cefaclor therapy. Allergy. 1992;47(4 Pt 2):439–40.

    Article  CAS  PubMed  Google Scholar 

  75. Rubin RL. Drug-induced lupus. Expert Opin Drug Saf. 2015;14(3):361–78.

    Article  CAS  PubMed  Google Scholar 

  76. Lowe GC, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2011;164(3):465–72.

    CAS  PubMed  Google Scholar 

  77. •• Fernandez TD, et al. Negativization rates of IgE radioimmunoassay and basophil activation test in immediate reactions to penicillins. Allergy. 2009;64(2):242–8 In this study, it is analyzed the loss of sensitivity of radioimmunoassay and BAT in patients reporting immediate allergic reactions to penicillin.

    Article  CAS  PubMed  Google Scholar 

  78. •• Gomez E, et al. Immunoglobulin E-mediated immediate allergic reactions to dipyrone: value of basophil activation test in the identification of patients. Clin Exp Allergy. 2009;39(8):1217–24 In this study, it is analyzed the negativization rate of BAT in patients reporting immediate allergic reactions to dipyrone.

    Article  CAS  PubMed  Google Scholar 

  79. Torres MJ, Padial A, Mayorga C, Fernandez T, Sanchez-Sabate E, Cornejo-Garcia JA, et al. The diagnostic interpretation of basophil activation test in immediate allergic reactions to betalactams. Clin Exp Allergy. 2004;34(11):1768–75.

    Article  CAS  PubMed  Google Scholar 

  80. Garvey LH, Krøigaard M, Poulsen LK, Skov PS, Mosbech H, Venemalm L, et al. IgE-mediated allergy to chlorhexidine. J Allergy Clin Immunol. 2007;120(2):409–15.

    Article  CAS  PubMed  Google Scholar 

  81. •• Kvedariene V, et al. Diagnosis of neuromuscular blocking agent hypersensitivity reactions using cytofluorimetric analysis of basophils. Allergy. 2006;61(3):311–5 In this study, it is analyzed the role of BAT in the diagnosis of immediate allergic reactions to NMBA, including the negativization rate over time.

    Article  CAS  PubMed  Google Scholar 

  82. Antunez C, Fernandez T, Blanca-Lopez N, Torres MJ, Mayorga C, Canto G, et al. IgE antibodies to betalactams: relationship between the triggering hapten and the specificity of the immune response. Allergy. 2006;61(8):940–6.

    Article  CAS  PubMed  Google Scholar 

  83. Fernandez T, Torres MJ, R-Pena R, Fuentes MS, Robles S, Mayorga C, et al. Decrease of selective immunoglobulin E response to amoxicillin despite repeated administration of benzylpenicillin and penicillin V. Clin Exp Allergy. 2005;35(12):1645–50.

    Article  CAS  PubMed  Google Scholar 

  84. Romano A, et al. Evaluation of adverse cutaneous reactions to aminopenicillins with emphasis on those manifested by maculopapular rashes. Allergy. 1995;50(2):113–8.

    Article  CAS  PubMed  Google Scholar 

  85. Romano A, Quaratino D, di Fonso M, Papa G, Venuti A, Gasbarrini G. A diagnostic protocol for evaluating nonimmediate reactions to aminopenicillins. J Allergy Clin Immunol. 1999;103(6):1186–90.

    Article  CAS  PubMed  Google Scholar 

  86. Romano A, Viola M, Mondino C, Pettinato R, di Fonso M, Papa G, et al. Diagnosing nonimmediate reactions to penicillins by in vivo tests. Int Arch Allergy Immunol. 2002;129(2):169–74.

    Article  CAS  PubMed  Google Scholar 

  87. Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168(3):555–62.

    Article  CAS  PubMed  Google Scholar 

  88. Asero R. Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria. J Allergy Clin Immunol. 2003;111(5):1095–8.

    Article  CAS  PubMed  Google Scholar 

  89. Doña I, Blanca-López N, Torres MJ, Gómez F, Fernández J, Zambonino MA, et al. NSAID-induced urticaria/angioedema does not evolve into chronic urticaria: a 12-year follow-up study. Allergy. 2014;69(4):438–44.

    Article  CAS  PubMed  Google Scholar 

  90. •• Doña I, et al. Natural evolution in patients with nonsteroidal anti-inflammatory drug-induced urticaria/angioedema. Allergy. 2017;72(9):1346–55 In this study, it is analyzed the natural evolution of cross-hypersensitivity to NSAIDs manifested as urtiaria/angioedema (NIUA).

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

I Doña holds a Juan Rodes research contract (JR15/00036) and NI Pérez-Sánchez holds a Rio Hortega contract (CM17/00141), both from the Carlos III National Health Institute, Spanish Ministry of Economy and Competitiveness (grants cofounded by European Social Fund, ESF).

Author information

Authors and Affiliations

  1. Allergy Unit, IBIMA-Regional University Hospital of Malaga-UMA, Malaga Regional University Hospital (Pavillion C, Hospital Civil), Pavillion 6, first floor, Plaza del Hospital Civil, 29009, Malaga, Spain

    Inmaculada Doña MD, PhD, María Salas MD, PhD, Natalia Isabel Pérez-Sánchez MD & María José Torres MD, PhD

  2. ARADyAL network RD16/0006/0001, Madrid, Spain

    Inmaculada Doña MD, PhD & María José Torres MD, PhD

  3. ARADyAL network RD16/0006/0021, Madrid, Spain

    María Salas MD, PhD

  4. Allergy Unit, IMIBIC-Reina Sofia University Hospital, Córdoba, Spain

    Carmen Moreno-Aguilar MD, PhD

  5. ARADyAL network RD16/0006/0018, Madrid, Spain

    Carmen Moreno-Aguilar MD, PhD

Authors
  1. Inmaculada Doña MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. María Salas MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Natalia Isabel Pérez-Sánchez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carmen Moreno-Aguilar MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. María José Torres MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Inmaculada Doña MD, PhD.

Ethics declarations

Conflict of Interest

Inmaculada Doña, María Salas, Natalia Isabel Pérez-Sánchez, Carmen Moreno-Aguilar and María José Torres declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Drug Allergy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Doña, I., Salas, M., Pérez-Sánchez, N.I. et al. Phenotypes and Natural Evolution of Drug Hypersensitivity. Curr Treat Options Allergy 6, 27–41 (2019). https://doi.org/10.1007/s40521-019-0200-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40521-019-0200-1

Keywords

Search

Navigation